Description
PHT-427 is an inhibitor of PDK1 and Akt that exhibits anticancer chemotherapeutic activity, inhibiting tumor growth in animal models of breast cancer and non-small cell lung cancer (NSCLC).
PHT-427
Product ID P3076
Cas No. 1191951-57-1
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1191951-57-1 |
|---|---|
| Purity | ≥98% |
| Formula | C20H31N3O2S2 |
| Formula Wt. | 409.61 |
| Chemical Name | 4-Dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide |
| IUPAC Name | 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide |
| Synonym | PHT427; PHT 427 |
| Solubility | DMSO 82 mg/mL (200.19 mM) Ethanol 60 mg/mL (146.48 mM) Water Insoluble |
| Appearance | White Crystal Powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
References
Meuillet EJ, Zuohe S, Lemos R, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17. PMID: 20197390.